NK Max "No Reason for Sharp Stock Drop... Strong Response to Malicious Rumors"

On the 24th, NKMAX stated that there are no internal issues that could cause problems in company management despite the sharp decline in stock price. The company also announced that it will take a strong stance against baseless rumors that damage shareholder value.

The company strongly denied market rumors about the possibility of being designated as a management item.

An NKMAX official said, “As the U.S. subsidiary NKGen Biotech has become an affiliate, losses from the U.S. subsidiary will not be reflected in the financial statements of the Korean corporation,” adding, “On the contrary, the Nasdaq listing of NKGen Biotech is expected to generate valuation gains on held shares, improving the financial structure.”

He continued, “We are currently focusing on various businesses to significantly increase sales this year.”

Based on the GMP approval received from the Japanese Ministry of Health, Labour and Welfare last November, NKMAX expects to generate sales from NK cell therapy products for the first time this year. The company is also preparing its cell therapy business through investment attraction and joint venture (JV) establishment in the Middle East region. Additionally, NKMAX plans to accelerate its entry into the Chinese and Southeast Asian markets by strengthening online sales of health functional food products.

This content was produced with the assistance of AI translation services.